Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant effects on left ventricular mass and cardiac function in active acromegaly
2006-001108-35Phase 4Terminated
- Sponsor
- Julius-Maximilians-Universität Würzburg
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegvisomant in acromegaly, sponsored by Julius-Maximilians-Universität Würzburg. Primary endpoint: Change in peak systolic strain rate. Started Apr 2006; status: terminated.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2006-001108-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001108-35.